Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
Gene patents survive Australian Senate enquiry – for now (Patentology)
EU guidelines clear way for biosimilar antibodies (GenericsWeb)
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
General
Australia: Gene patents survive Australian Senate enquiry – for now (Patentology)
China: Why China is preferred over India by the US pharmaceutical industry (IP Dragon)
China: Parasiting trademarks of drugs in China breeds resistant malaria parasite (IP Dragon)
EU guidelines clear way for biosimilar antibodies (GenericsWeb)
EU: SPCs and the ‘salt’ problem no 2 (The SPC Blog)
UK: Cephalon v Orchid – a path less clear? (Kluwer Patent Blog)
US: Legal setbacks and legislative inaction may push the FTC to consider “plan c” to address patent settlement agreements (FDA Law Blog)
US: FTC continues attempts to block reverse payments (Patent Docs)
US: Is the Myriad case decision and/or the DOJ brief TRIPS compliant? (PatentlyBIOtech)
US: Alzheimer’s Institute of America files patent infringement suit against Avid Radiopharmaceuticals (Patent Docs)
US: Regeneron files for declaratory judgment of non-infringement/invalidity of Genetech patents based on its planned biological license application for VEGF Trap (Patent Docs)
US: Life Technologies files patent infringement suit against Genmark based on eSensor system (Patent Docs)
Products
Advair (Fluticasone propionate/Salmeterol) – Netherlands: Dutch court case to test patent on Glaxo’s Advair (GenericsWeb)
Afrin / Ephrine – Israel: Afrin and Ephrine, confusingly similar or not? TM 216996 – Schering Plough (The IP Factor)
Concerta (Methylphenidate) – US: Impax Laboratories confirms patent suit relating to generic Concerta 54 mg tablets (SmartBrief)
Hycamtin (Topotecan) – US: APP Pharmaceuticals announces approval and launch of Topotecan for injection (SmartBrief)
Lovaza (Omega-3) – US: Pronova Biopharma receives Lovaza paragraph IV notice letter from Apotex Inc (GenericsWeb)
Naropin (Ropivacaine) – UK: Assigned or not? Abraxis Bioscience, Inc. v. Navinta LLC (Property, intangible)
Pulmicort Respules (Budesonide) – US: Liability for future indirect infringement: AstraZeneca LP v. Apotex, Inc (Patently-O)
Simcor (Niacin/Simvastatin) – US: Impax Laboratories confirms patent challenge relating to Simcor extended-release tablets (SmartBrief)
Taxotere (Docetaxel) – EU: Actavis launches Docetaxel single vial on patent expiry in major European markets (GenericsWeb)
Temodar (Temozolide) – US: Cancer Research Technology files patent infringement suit against Accord following Para IV certification filing (Patent Docs)
Tri-Cyclen Lo (Norgestimate/ethinyl estradiol) – US: Ortho-Mcneil-Janssen files patent infringement suit against Mylan following Para IV certification (Patent Docs)